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BACKGROUND: Annexin II (ANX2) is a multi-functional protein involved in cell proliferation and membrane physiology and is related to
cancer progression. The purpose of this study was to assess ANX2 expression in clear-cell (cc) renal cell carcinoma (RCC).
METHODS: The ANX2 expression in 18 primary ccRCCs was examined by real-time reverse transcriptase (RT)–PCR and western blot
analyses. Furthermore, immunohistochemical study was performed using paraffin section of 154 primary ccRCCs and 24 metastases.
The association between ANX2 expression and the clinicopathological factors and prognosis was analysed.
RESULTS: The ANX2 was upregulated at both mRNA and protein levels in 14 of 18 primary ccRCCs. Immunohistochemical analysis
showed that ANX2 was positive in 73 (47.4%) of 154 primary ccRCC and in 21 (87.5%) of 24 metastatic tumours. The ANX2
expression in the primary tumours showed significant associations with a higher stage, a higher nuclear grade. In patients without
metastasis, the 5-year metastasis-free rate in patients with ANX2-positive tumour was significantly lower than that in those with
ANX2-negative tumour (63.0% vs 90.1%; Po0.0001). Multivariate analysis showed that ANX2 expression is an independent
predictor for metastasis.
CONCLUSION: Our findings suggest that ANX2 expression might be a novel predictor of the metastatic potential of ccRCC.
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Renal cell carcinomas (RCCs) account for B3% of adult tumours.
The RCCs comprise a heterogeneous group of tumours with
distinct genetic backgrounds and different biological character-
istics. The most common subtype of RCC is clear-cell RCC
(ccRCC), which represents over 80% of RCCs (Srigley, 2004). The
widespread use of non-invasive imaging techniques (ultrasono-
graphy, computed tomography and magnetic resonance imaging)
for abdominal screening or unrelated disorders has led to a
migration towards earlier stages at diagnosis, with increased
numbers of asymptomatic small renal tumour being detected.
These incidentally detected RCC have a more favourable prognosis
than symptomatic RCC (Pantuck et al, 2000). The Tumor-Node-
Metastasis (TNM) stage and nuclear grade are currently widely
accepted prognostic factors (Shuch et al, 2006), however, some
patients infrequently follow unexpected clinical course such as late
recurrence. Thus, the identification of additional prognostic
markers more strictly related to the intrinsic biological behaviour
of RCC may be helpful to plan postoperative follow-up protocol in
individual patient, as well as to prevent the unnecessary use of
adjuvant therapy.
Recently, we succeeded in establishing two RCC cell lines, which
were derived from a matched pair of a primary RCC and its
adrenal metastasis (Ohno et al, 2008). Proteomic analysis showed
that annexin A2 (ANX2) is one of the proteins that are
differentially expressed between these cell lines. The ANX2, a
34–36kDa protein, belongs to a family of Ca
2þ-dependent
phospholipids and membrane-binding proteins. The ANX2 is
involved in specific functions that depend on its intracellular
localisation, such as DNA synthesis in the nucleus, protein
transportation in the cytoplasm. Further, on the cell surface it
functions as a receptor for tissue-type plasminogen activator and
tenascin-C (Gerke et al, 2005). As for the role in cancer, it is
reported that overexpression of ANX2 is associated with progres-
sion and metastasis in various types of cancer, including brain
tumour (Reeves et al, 1992), pancreatic cancer (Diaz et al, 2004;
Esposito et al, 2006), gastric cancer (Emoto et al, 2001a) and
colorectal cancer (Emoto et al, 2001b). Recently, an in vitro study
of rat RCC showed an association between ANX2 overexpression
and metastasis (Tanaka et al, 2004). In addition, another report
showed that ANX2 expression correlated with higher nuclear grade
of the tumour and poor clinical outcome, although the study
included only 33 cases (Zimmermann et al, 2004). These findings
imply that ANX2 may be involved in the metastatic process in
RCC. Therefore, in this study, we investigated the ANX2
expression in primary tumours in the context of its prognostic
significance in RCC and RCC metastases.
MATERIALS AND METHODS
Clinical samples
Fresh frozen surgical specimens and formalin-fixed paraffin-
embedded tissues were obtained from patients with ccRCC who
were treated at the Tokyo Medical University Hospital. The
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sinformed consent for the use of the samples was obtained from
each patient.
Fresh frozen surgical specimens of primary tumour tissue paired
with normal renal cortical tissue were obtained from 18 patients,
who were treated between January 2004 and February 2008, at the
time of nephrectomy and stored at  801C until use. A total of 10
patients had T1 tumours, two had T2 tumours and six had T3
tumours. One tumour was graded as 1; eight as grade 2; nine as
grade 3 or 4. At the time of diagnosis, seven patients had metastatic
disease, and one patient developed metastasis during follow-up. In
addition, formalin-fixed paraffin-embedded tissues were obtained
from 161 patients who were treated between September 1986 and
September 2003, which included 154 primary ccRCCs and 24
metastatic tumours of ccRCCs. The metastatic tissue samples were
obtained by surgical resection or tumour biopsy. The sites of
metastasis were as follows: bone (n¼5), lymph node (n¼2),
adrenal gland (n¼3), skin (n¼3), lung (n¼2), brain (n¼2),
parotid gland (n¼2), thyroid gland (n¼1), ovary (n¼1), gall
bladder (n¼1), retroperitoneal tissue (n¼1) and soft tissue
(n¼1). The samples included 15 matched pairs of primary
tumours and their metastases. The mean age of these 161 patients
(117 men and 44 women) at the time of diagnosis was 59 years
(range 24–81 years). A total of 154 patients had undergone radical
nephrectomy at our hospital. Extended lymphadenectomy was not
included in the routine procedure of nephrectomy, but regional
lymph node dissection was performed if enlarged or palpable
lymph nodes were recognised. No patient received irradiation or
chemotherapy before surgery. The tumours were staged according
to the 1997 TNM staging system: 79 were TNM stage I, 12 were
stage II, 28 were stage III and 35 were stage IV. The histological
types were determined according to the World Health Organiza-
tion classification. Nuclear grading was performed according to
the Fuhrman’s nuclear grading system: 48 tumours were graded as
1; 68 as grade 2; 38 as grade 3 or 4. All patients were followed-up
with clinical and radiological examinations at regular intervals.
Patients with metastatic disease received interferon-a or inter-
leukin-2 therapy. At the last follow-up, 76 patients showed no
evidence of disease, 29 patients were alive with metastases, 46
patients had died of cancer and 10 patients had deceased because
of other events. The mean follow-up period was 89.9 months
(range, 1–261 months).
Real-time RT–PCR
A total of 18 pairs of primary RCC and normal renal cortex were
used in this analysis.
The total RNA from surgically resected tissues was extracted using
the Isogen reagent (Nippon Gene, Toyama, Japan) in accordance with
the manufacturer’s instructions. The sequence of primer sets used was
as follows: ANX2 forward primer, 50-TGAGCGGGATGCTTTGAAC-30;
ANX2 reverse primer, 50-ATCCTGTCTCTGTGCATTGCTG-30; b-actin
forward primer, 50-ATTGCCGACAGGATGCAGA-30; b-actin reverse
primer, 50-GAGTACTTGCGCTCAGGAGGA-30.T h eb-actin was run
in each PCR reaction and used as an internal control. Real-time
reverse transcriptase (RT)–PCR was performed using a SmartCycler
system (Cephied, Sunnyvale, CA, USA). The RT–PCR was carried out
using a one-step SYBR RNA PCR Kit II (Perfect real time; Takara
Biomedical, Tokyo, Japan) according to the manufacturer’s instruc-
tions. The total RT–PCR reaction volume was 25ml and contained
2 One Step SYBR RT-RNA PCR buffer4 (containing the dNTP
Mixture, Mg
2þ and SYBR Green I), PrimerScript 1step Enzyme Mix2,
20ng of sample RNA and 400nM of each oligonucleotide primer. The
initial steps of RT–PCR were performed for 5min at 421Cf o l l o w e db y
a1 0 sh o l da t9 5 1C. Thereafter, 45 cycles consisting of a 5s melt at
951C, followed by a 30s annealing/extension at 601C were performed.
The denaturation curve was drawn at the end of the reaction to
confirm the melting temperature of the specific PCR product. No
template (H2O) control was included in each reaction run.
The cycle threshold (Ct) value, which is the cycle number at the
point where the fluorescence rises above the background noise,
was determined using the second derivative method (Luu-The
et al, 2005). In the second derivative method, the Ct corresponds to
the first peak of a second derivative curve. This peak corresponds
to the beginning of a log-linear phase. The relative amount of
ANX2 gene transcript normalised to b-actin was determined by the
difference in their Ct value (DCt) (Hamalainen et al, 2001).
DCt ¼ Ctb-actin   CtANX2
Western blot analysis
A total of 18 pairs of primary RCC and normal renal cortex were used
in this analysis. Whole-tissue protein extracts were collected after
sonication with 2 sample buffer (containing 0.25M Tris-HCl, 10%
2-Mercaptoethanol, 4% sodium dodecyl sulphate and 10% sucrose).
The protein concentration was determined using a Bio-Rad Protein
Assay Kit (Bio-Rad Laboratories, Hercules, CA, USA). A total of 10mg
of protein from each sample was run on a 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) gel. The
proteins were then transferred onto nitrocellulose membranes
(Bio-Rad Laboratories) with a Trans-Blot SD Semi-Dry Transfer
Electrophoretic Transfer Cell (Bio-Rad). Non-specific binding was
b l o c k e dw i t hp h o s p h a t e - b u f f e r e ds a l i n ec o n t a i n i n g0 . 1 %T w e e n2 0a n d
5% non-fat dried milk for 2h at room temperature. The membrane
was probed with rabbit anti-human annexin II polyclonal antibody
(dilution at 1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
for 1h at room temperature. The membrane with bound antibodies
was then incubated with anti-rabbit horseradish peroxidase-con-
jugated IgG secondary antibody (dilution at 1:1200, Amersham
Pharmacia, Piscataway, NJ, USA) for 1h at 371C. Immunoreactive
proteins were detected with an enhanced chemiluminescence detec-
tion kit (Amersham Pharmacia) and LumiVision HS (Taitec Co.,
Tokyo, Japan). Subsequently, the membranes were stripped off the
first probe by using Restore Western Blot Stripping Buffer (Pierce,
Rockford, IL, USA) and reprobed with mouse anti-human b-actin
monoclonal antibody (dilution at 1:2000; Sigma-Aldrich, St Louis,
MO, USA). The secondary antibody used for anti-human b-actin
antibody was anti-mouse horseradish peroxidase-conjugated IgG
antibody (dilution at 1:2000, Amersham Pharmacia). Densitometric
analysis was performed by using a LumiVision analyzer (Taitec Co.,
Tokyo, Japan). The ANX2 protein level was expressed with the relative
ratio (RR), which was calculated by the following formula using signal
intensity (SI) of ANX2 and b-actin.
RR ¼ SIANX2=SIb-actin
NIH/3T3 whole-cell lysate (sc-2210, Santa Cruz Biotechnology) was
used as the positive control.
Immunohistochemistry
The sections (4-mm-thick) from archival formalin-fixed paraffin-
embedded tissues of a representative area of the surgical specimens,
which included the highest nuclear grade cancer, were mounted on
poly-L-lysine coated slides. They were deparaffinised with xylene and
rehydrated through a graded alcohol series. Endogeneous peroxidase
was blocked by incubation with 3% hydrogen peroxide for 20min.
Antigen retrieval (1211Cf o r1 0m i ni n1 0m M citrate buffer, pH 6.0)
was then performed. Endogenous biotin was blocked by incubation
with 0.01% biotin for 20min at room temperature. After blocking
non-specific conjugation with 1% casein, the slides were incubated
for 60min at room temperature with anti-annexin II rabbit
polyclonal antibody (dilution at 1:50; Santa Cruz Biotechnology).
Bound antibodies were detected by the avidin–biotin complex
peroxidase method (Vectastain ABC Kit, Vector Laboratories,
Burlingame, CA, USA) and visualised with diaminobenzidine. The
slides were counterstained in Harris’ hematoxylin, dehydrated and
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smounted. Sections of benign prostate tissue were used as positive
control. As negative control, the primary antibody was omitted and
substituted with normal rabbit IgG.
The ANX2 expression was considered to be positive if 410% of
the cancer cells were clearly stained in each slide under
microscopic observation.
Statistical analysis
All statistical analyses were performed using JMP Ver. 5.1 (SAS
Institute Inc., Cary, NC, USA). The ANX2 gene by real-time RT–
PCR and ANX2 protein expression by western blot were assessed
using paired t-test. In immunohistochemical analysis, ANX2
expression was considered as a dichotomous variable (i.e., positive
or negative) in all the statistical analyses. The correlation between
ANX2 expression and other clinicopathological factors was
assessed using a w-square test, Fisher’s exact test and Student’s
t-test. The metastasis-free and cancer-specific survival rates were
estimated by the Kaplan–Meier method, and the differences
between the curves were tested using the log-rank test. Metastasis-
free time was calculated from the date of radical nephrectomy to
the date of radiological detection of metastases. A multivariate
analysis using the Cox proportional hazards regression model was
used to test for independent prognostic values. P-values o0.05
were considered statistically significant.
RESULTS
Annexin II expression in primary RCC tissues: results of
real-time RT–PCR and western blot analysis
A total of 18 pairs of primary kidney cancer and a corresponding
normal renal cortex were analysed. The ANX2 was upregulated at
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Figure 1 Annexin II (ANX2) expression in primary kidney cancer. (A) The ANX2 expression at mRNA level was analysed in 18 pairs of primary clear-cell
renal cell carcinoma (T) and the corresponding normal renal cortex (N). The ANX2 was significantly upregulated in 14 primary tumours (P¼0.0086).
(B) Western blot analysis showed ANX2 expression was higher in 14 of 18 primary tumours compared with the corresponding normal renal cortex;
however, the difference was not significant. The relative ratio (RR) is calculated using signal intensity of ANX2 and b-actin. (C) Representative examples of
ANX2 protein expression in primary kidney cancer. After normalising the signal intensity of ANX2, the ANX2 expression in each sample was evaluated on
the basis of the ratio of the primary kidney cancer to the corresponding normal renal cortex. Patients 1–3 showed no evidence of metastasis, patient 4
developed metastasis 3 years after nephrectomy, and patients 5 and 6 showed metastasis at the time of diagnosis.
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comparison to the corresponding normal renal tissues; especially,
the DCT value of tumour (mean±s.d.,  3.07±0.71) was
significantly higher than those of the corresponding normal renal
tissue (mean±s.d.,  3.80±0.76) (P¼0.0086) (Figure 1A and B).
Representative examples of ANX2 expression by western blot
analysis are shown in Figure 1C. The primary kidney cancer (T)/
the corresponding normal renal cortex (N) ratio of ANX2
expression was 0.33–5.73 (mean ratio, 1.96). The mean T/N ratio
in patients with metastasis (mean±s.d., 2.62±0.44) was more
likely to be higher than that in those without metastasis
(mean±s.d., 1.44±0.39) (P¼0.0617).
Annexin II expression in paraffin-embedded primary
kidney cancer and its metastases: results of
immunohistochemistry
Immunohistochemical analysis of 154 primary RCCs and 24
metastatic tumours was performed. The ANX2 staining was
observed on the cell membranes or in the cytoplasm. The ANX2
staining was heterogenous in the tumour sections, and the staining
intensity was relatively higher in the periphery of the tumour and
around vessels (Figure 2A–D). Finally, 73 (47.4%) of the 154
primary RCCs and 21 (87.5%) of the 24 metastatic tumours were
considered to be positive for ANX2. There was a significant
AB
CD
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GH
Figure 2 Immunohistochemical staining of ANX2 in primary RCC and its metastases. (A) Grade 1 clear-cell carcinoma, (B) grade 2 clear-cell carcinoma,
(C, D) ANX2 is highly expressed along the periphery and around vessels. (E) Lung metastasis, (F) bone metastasis, (G) neck lymph node metastasis and
(H) brain metastasis. Magnification at  20; Scale bar, 100mm.
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and its metastasis (P¼0.00028). Among the 15 matched pairs of
primary RCC and its metastasis, both components were positive
for ANX2 in 12 pairs. Representative images of the metastatic
tumours (lung, lymph node, bone and brain) are also shown in
Figure 2E–H.
Correlation between annexin II expression and
clinicopathological factors
Table 1 shows the correlation between ANX2 expression in
primary RCC and clinicopathological factors in the 154 patients
who underwent nephrectomy. The ANX2 expression was more
frequent in tumours of a higher TNM stage (Po0.0001), higher T
stage (P¼0.0006) and higher nuclear grade (Po0.0001). The M1
stage (P¼0.0003) and microscopic venous invasion (P¼0.007)
were also associated with ANX2 positivity.
Prognostic significance of annexin II expression in RCC
To assess the prognostic significance of ANX2 expression in RCC,
we analysed cancer progression (metastasis) and survival in
relation to ANX2 expression in primary tumour.
The relationship between clinicopathological factors and pro-
gression was analysed in 119 patients with stages 1–3 disease.
A total of 41 patients developed metastases during their clinical
course. The median time to radiological appearance of metastases
was 50.5 months (range, 1.5–184 months). The following were the
first recognised sites of metastasis: the lung in 26 cases, bone in 4
cases, liver in 1 case, adrenal gland in 1 case, retroperitoneal space
in 4 cases and others in 5 cases. Metastasis-free rate was estimated
using the Kaplan–Meier method. There was a significant inverse
correlation between metastasis-free rate and the TNM stage
(P¼0.0003) or nuclear grade (P¼0.0001) of the tumour.
Microscopic venous invasion did not have significant influence
on the development of metastasis. As for ANX2 expression, the
metastasis-free rate in patients with ANX2-positive primary RCC
was 63.0% over 5 years and 46.5% over 10 years; this rate was
significantly lower than the 90.1% 5-year metastasis-free survival
and 83.6% 10-year metastasis-free survival observed in patients
with ANX2-negative primary RCC (Po0.0001) (Figure 3). Multi-
variate analysis with a Cox proportional hazard model showed that
ANX2 expression was an independent predictor for metastasis
(P¼0.021; Table 2).
With regard to cancer-specific survival, there were significant
differences in TNM stage (Po0.0001), nuclear grade (Po0.0001),
microscopic venous invasion (P¼0.0011) and ANX2 expression of
the primary RCC (P¼0.0025). However, multivariate analysis
showed that only TNM stage and nuclear grade were independent
prognostic factors for survival (TNM stage, Po0.0001; nuclear
grade, P¼0.0002) (Table 2).
Table 1 Correlation between annexin II expression and clinicopatho-
logical factors
Negative (%) Positive (%) P-value
Age (years) 57.3 60.1 NS
Size (cm) 5.3 6.9 0.0028
Gender
Male 50 (44.6) 62 (55.4) 0.001
Female 31 (73.8) 11 (26.2)
TNM stage
I 58 (73.4) 21 (26.6) o0.0001
II 4 (33.3) 8 (66.7)
III 10 (35.7) 18 (64.3)
IV 9 (25.7) 26 (74.3)
T stage
T1 58 (66.7) 29 (33.3) 0.0006
T2 9 (42.9)) 12 (57.1)
T3 13 (31.7) 28 (68.3)
T4 1 (20.0) 4 (80.0)
M stage
0 74 (59.7) 50 (40.3) 0.0003
1 7 (23.3) 23 (76.7)
Grade
1 37 (77.1) 11 (22.9) o0.0001
2 32 (47.1) 36 (52.9)
3 or 4 12 (31.6) 26 (68.4)
Microscopic venous invasion
Negative 63 (60.0) 42 (40.0) 0.007
Positive 18 (36.7) 31 (63.3)
1.0
0.5
Months
Months
P < 0.0001
P = 0.0025
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Figure 3 Metastasis-free survival rates in patients with stages 1–3 and
the cancer-specific survival rates. The metastasis-free survival rates were
estimated by the Kaplan–Meier method, and the differences between
curves were tested using the log-rank test. (A) The metastasis-free survival
rates in patients with stages 1–3 disease (n¼119). The metastasis-free
time was calculated from the date of radical nephrectomy to the date of
radiological detection of metastases. The metastasis-free survival rate of
patients with ANX2-positive primary tumour was significantly lower than
that of patients with ANX2-negative primary tumour (Po0.0001).
(B) Cancer-specific survival rates (n¼154). The survival rate of patients
with ANX2-positive primary tumour was significantly lower than that of
patients with ANX2-negative primary tumor (P¼0.0036).
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sDISCUSSION
In this study, we investigated the ANX2 expression in primary
ccRCCs and their metastases. In agreement with earlier reports
(Unwin et al, 2003; Domoto et al, 2007), ANX2 expression was
upregulated in primary RCC compared with the corresponding
normal renal cortex at mRNA and protein levels. Furthermore,
western blot analysis showed that ANX2 protein level was more
likely to be higher in primary tumours that developed metastases
than in those that did not, as described in earlier report of rat RCC
model (Tanaka et al, 2004). In immunohistochemical study, ANX2
was positive in 73 (47.4%) of the 154 primary ccRCCs and in 21
(87.5%) of the 24 metastatic tumours. The ANX2 positivity in
primary tumour was clearly associated with advanced stage and a
higher nuclear grade. Univariate and multivariate analysis showed
that the immunohistochemical expression of ANX2 in a primary
tumour is an independent predictor of metastasis.
The ANX2, a 34–36kDa protein, is a multi-functional protein
involved in cell proliferation and membrane physiology (Gerke
et al, 2005). The dysregulation of ANX2 expression has been
reported in various types of cancers, thus far. Upregulation of
ANX2 expression has been reported in hepatocellular carcinoma
(Frohlich et al, 1990), lung cancer (Cole et al, 1992), pancreatic
cancer (Diaz et al, 2004; Esposito et al, 2006), breast cancer
(Sharma et al, 2006), gastrointestinal cancer (Singh, 2007), glioma
(Reeves et al, 1992) and colorectal cancer (Emoto et al, 2001b).
Conversely, downregulation of ANX2 expression has been reported
in prostate cancer (Chetcuti et al, 2001; Banerjee et al, 2003; Liu
et al, 2003), osteosarcoma (Gillette et al, 2004), oesophageal
squamous cell carcinoma (SCC) (Zhi et al, 2003) and head and
neck SCC (Pena-Alonso et al, 2008). This discrepancy may be
explained by ANX2 expression in the histological origin of
tumours, the cellular localisation and the putative function of
ANX2 in tumour cells. The ANX2 exists as a monomer in the cell
cytoplasm or as a heterotetramer complexed with S100A10 in
association with the plasma membrane. The ANX2 heterotetramer
acts as a receptor for plasminogen, tissue-type plasminogen
activator and tenascin C, and is implicated in extracellular matrix
degradation (Gerke et al, 2005). The ANX2 is not observed in
normal hepatocytes, the pancreatic exocrine system and the
mammary gland (Frohlich et al, 1990; Dreier et al, 1998; Massey-
Harroche et al, 1998); in tumours that arise from these tissues,
such as hepatocellular carcinoma, pancreatic cancer and breast
cancer, respectively, ANX2 expression is observed as membrane
and/or cytoplasmic staining (Frohlich et al, 1990; Diaz et al, 2004;
Sharma et al, 2006). Esposito et al (Esposito et al, 2006) reported
that ANX2 expression changed from cytoplasmic to cell
surface expression with progression of pancreatic cancer.
Table 2 Univariate and multivariate analysis of metastasis-free and cancer-specific survival rate
Metastasis free (%)
5 years 10 years Log-rank test Likelihood Ratio Chi-square Cox
TNM stage
1 89.6 81.7 0.0003 3.2923 0.1928
2 75.0 42.9
3 52.5 46.7
Nuclear grade
1 88.5 82.9 0.0001 3.9556 0.1384
2 79.5 68.0
3 or 4 43.3 34.7
Microscopic venous invasion
Negative 81.8 73.1 NS
Positive 74.1 60.2
Annexin II expression
Negative 90.1 83.6 o0.0001 5.3228 0.021
Positive 63.0 46.5
Cancer-specific survival (%)
5 years 10 years Log-rank test Likelihood Ratio Chi-square Cox
TNM stage
1 94.4 90.4 o0.0001 26.7984 o0.0001
2 91.8 73.3
3 74.1 63.6
4 25.2 0.0
Nuclear grade
1 97.6 97.6 o0.0001 17.0858 0.0002
2 81.3 69.0
3 or 4 42.0 33.7
Microscopic venous invasion
Negative 83.4 77.6 0.0011 0.0748 0.7845
Positive 63.4 53.9
Annexin II expression
Negative 84.2 81.9 0.0025 0.1022 0.7492
Positive 66.5 54.8
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surface of an invasive/metastatic breast cancer cell line and that
ANX2-dependent localised plasmin generation by breast cancer cells
could contribute to angiogenesis and metastasis. These reports
suggest that membrane-associated ANX2 is involved in the
degradation of the extracellular matrix, which is required
for tumour invasion. On the other hand, it is reported that ANX2
expression is lost as benign prostatic epithelium progresses to
prostate cancer (Chetcuti et al, 2001). The ANX2 is normally
observed in the prostate gland, wherein it localises in the cytoplasm
and intracellular side of the plasma membrane and is involved in
tethering cytoskeletal proteins or vesicle transport (Liu et al, 2003;
Gerke et al, 2005). Liu et al reported that the re-expression of ANX2
inhibited the migration of prostate cancer cells and that a reduction
or loss in ANX2 expression may contribute to prostate cancer
development and progression. However, it is also reported that
ANX2 is re-expressed in poorly differentiated prostate cancer and
that ANX2 expression is observed in the metastatic androgen-
unresponsive PC-3 and DU-145 cell lines (Banerjee et al, 2003; Yee
et al, 2007). The ANX2 protein may change its distribution or is re-
expressed and plays different roles with tumour progression even in
the same tumour.
With regard to RCC, the functions of ANX2 have not been fully
elucidated. As reported by Zimmermann et al, we also showed that
ANX2 was highly expressed in the periphery of the tumour and
around the vessels. Furthermore, in our current 15 matched pairs
of a primary tumour and corresponding metastatic tumour, both
components were positive for ANX2 in 12 pairs. It is speculated
that ANX2 might be associated with extracellular matrix degrada-
tion and ANX2-positive tumour cell develop metastasis.
Distant metastasis is a major clinical determinant of the
outcome of RCC. However, RCCs occasionally follow an unpre-
dictable course involving events such as late recurrence over a
decade after nephrectomy. Thus, it is important to identify reliable
prognostic markers to establish individualised follow-up protocols.
In this study, we showed that ANX2 expression in ccRCC was
associated with metastasis and poor prognosis. The ANX2 might
play an important role in the development of metastasis and might
be a useful marker for formulating individualised follow-up
protocols as well as for identifying patients suitable for adjuvant
therapy.
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